← Return to Webinar: What Women Need to Know about Ovarian Cancer

Event
Webinar: What Women Need to Know about Ovarian Cancer May 12, 2015 | 12:00pm - 1:00pm ET

Comment receiving replies
@above

Please share your latest research on best preventing ovarian cancer from recurring (non hereditary, stage 3B after major hysterectomy))

Jump to this post


Replies to "Please share your latest research on best preventing ovarian cancer from recurring (non hereditary, stage 3B..."

At Mayo there is currently a vaccine trial open (MC1361; clinicaltrials.gov identifier: NCT02111941) for women who have completed radical surgery, chemotherapy and have no evidence of active cancer. For more details, please visit: http://www.mayo.edu/research/clinical-trials/cls-20110798.

We are also in the process of opening a phase III clinical trial (GOG 3005) that would randomize women to receive a PARP inhibitor during their initial chemotherapy. One-third of the women on that study will continue the PARP inhibitor as maintenance after they have completed chemotherapy. This trial will be open for women with newly-diagnosed ovarian cancer.

Dear Alex
Thank you for your reply. Are the clinical trials open to non-americans? Im Danish and might be willing to travel:-)
Best rgs
A

Sendt fra min iPhone
derfor lidt kort 🙂
bedste hilsner Anne

Yes, international patients are eligible to participate. However, I would suggest you consider staying in the US rather than trying to travel back and forth. In addition, you should have complete records submitted with your “new patient registration” with a specific question to the Medical Oncology team to review candidacy for clinical trials prior to making an appointment. This could save you the potential problem of being disqualified based on prior treatments or other criteria.